18F-FDG PET and Perfusion SPECT in the Diagnosis of Alzheimer and Lewy Body Dementias
Open accessAbstract
UNLABELLED: Brain imaging with glucose ((18)F-FDG) PET or blood flow (hexamethylpropyleneamine oxime) SPECT is widely used for the differential diagnosis of dementia, though direct comparisons to clearly establish superiority of one method have not been undertaken. METHODS: Subjects with Alzheimer disease (AD; n = 38) and dementia with Lewy bodies (DLB; n = 30) and controls (n = 30) underwent (18)F-FDG PET and SPECT in balanced order. The main outcome measure was area under the curve (AUC) of receiver-operating-characteristic analysis of visual scan rating. RESULTS: Consensus diagnosis with (18)F-FDG PET was superior to SPECT for both dementia vs. no-dementia (AUC = 0.93 vs. 0.72, P = 0.001) and AD vs. DLB (AUC = 0.80 vs. 0.58, P = 0.005) comparisons. The sensitivity and specificity for dementia/no-dementia was 85% and 90%, respectively, for (18)F-FDG PET and 71% and 70%, respectively, for SPECT. CONCLUSION: (18)F-FDG PET was significantly superior to blood flow SPECT. We recommend (18)F-FDG PET be performed instead of perfusion SPECT for the differential diagnosis of degenerative dementia if functional imaging is indicated.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
FDG-PET has superior diagnostic accuracy in AD and DLB compared to HMPAO SPECT, with an AUC of 0.93 for FDG-PET versus 0.72 for HMPAO SPECT.
“FDG-PET was found to have superior diagnostic accuracy in AD and DLB compared to hexamethylpropyleneamine oxime (HMPAO) SPECT with an AUC of 0.93 for FDG-PET compared to 0.72 for HMPAO SPECT [110].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [110]
FDG-PET cannot be used as an indicative biomarker for DLB.
“Larger studies however have shown that FDG-PET has sensitivity of 74% and specificity of 70% for DLB and therefore cannot be used as an indicative biomarker [21, 110].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [110]
Larger studies have shown FDG-PET has sensitivity 74% and specificity 70% for DLB.
“Larger studies however have shown that FDG-PET has sensitivity of 74% and specificity of 70% for DLB and therefore cannot be used as an indicative biomarker [21, 110].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [110]
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568 · see citing works
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069 · see citing works
Self-citationJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072 · see citing works
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476 · see citing works
Self-citationAghourian, M., Legault-Denis, C., Soucy, J.-P., Rosa-Neto, P., Gauthier, S., Kostikov, A., Gravel, P., & Bédard, M.-A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.183 · Cited by 220 · see citing works
The use of neuroimaging techniques in the early and differential diagnosis of dementia
Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 186 · see citing works
“Larger studies however have shown that FDG-PET has sensitivity of 74% and speci fi city of 70% for DLB and therefore cannot be used as an indicative biomarker [21, 110].”
BackgroundResultInfluentialSelf-citationDementia with Lewy bodies: Challenges in the diagnosis and management
Chin, K. S., Teodorczuk, A., & Watson, R. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419835029 · Cited by 63 · see citing works
Unified theory of Alzheimer’s disease (UTAD): implications for prevention and curative therapy
Nehls, M. (2016) · Journal of Molecular Psychiatry · doi:10.1186/s40303-016-0018-8 · Cited by 41 · see citing works
Differentiating Dementia with Lewy Bodies and Alzheimer's Disease by Deep Learning to Structural MRI
Nemoto, K., Sakaguchi, H., Kasai, W., Hotta, M., Kamei, R., Noguchi, T., Minamimoto, R., Arai, T., & Asada, T. (2021) · Journal of Neuroimaging · doi:10.1111/jon.12835 · Cited by 37 · see citing works
Hudd, F., Shiel, A., Harris, M., Bowdler, P., McCann, B., Tsivos, D., Wearn, A., Knight, M., Kauppinen, R., Coulthard, E., et al. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180879 · Cited by 26 · see citing works
- Authors
- O’Brien, J. T., Firbank, M. J., Davison, C., Barnett, N., Bamford, C., Donaldson, C., Olsen, K., Herholz, K., Williams, D., & Lloyd, J.
- Affiliations
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Newcastle University (GB)
- Glasgow Caledonian University (GB)
- University of Manchester (GB)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2014-11-05
- Volume
- 55
- Issue
- 12
- Pages
- 1959-1965
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2003527317
- Cited by
- 192
- References
- 4
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 10 · 2023: 17 · 2022: 11 · 2021: 15 · 2020: 47 · 2019: 18 · 2018: 22 · 2017: 17 · 2016: 18 · 2015: 7
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- ResearchOnline (Glasgow Caledonian University) (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- ResearchOnline (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Funders
- National Institute for Health and Care Research (PB-PG-1207-13105)
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- 18F-FDG PET, perfusion SPECT, Alzheimer's disease, dementia with Lewy bodies, differential diagnosis of dementia, glucose metabolism imaging, cerebral blood flow imaging, diagnostic accuracy, degenerative dementia
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Neuropsychological Tests, Perfusion, Prospective Studies, Tomography, Emission-Computed, Single-Photon, Technetium Tc 99m Exametazime, Fluorodeoxyglucose F18, Lewy Body Disease, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
